CoChat

Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers

Open access
Adem, Camilo, Reynolds, Carol, Soderberg, Cheryl L., Slezak, Jeffrey M., McDonnell, Shannon K., Sebo, Thomas J., Schaid, Daniel J., Myers, Jeffrey L., Sellers, Thomas A., Hartmann, Lynn C., Jenkins, Robert B. · 2003 · Cancer
Cited by 85

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

BACKGROUND: BRCA1 and BRCA2 alterations are associated with an increased risk of developing breast carcinoma. The authors hypothesized that the progression of breast neoplasia may differ between patients with hereditary disease and patients with nonhereditary disease and that this difference in progression may be visualized by studying the prevalence of precursor lesions and neoplastic lesions. METHODS: The authors developed two case cohorts of high‐risk patients with a strong family history of breast carcinoma who underwent prophylactic mastectomy. The first cohort was comprised of women who underwent therapeutic mastectomy and contralateral prophylactic mastectomy, and the second cohort was comprised of women who underwent bilateral prophylactic mastectomy. Patients without a family history of breast carcinoma who underwent unilateral or bilateral prophylactic mastectomy were selected as a control group. DNA from peripheral blood leukocytes was screened for BRCA1 and BRCA2 mutations. The available pathologic materials were reviewed independently by two pathologists, and all neoplastic and precursor lesions were identified and classified. Proliferation activity was assessed using MIB‐1 immunohistochemistry on all available lesions from the unilateral mastectomy cohort. RESULTS: The 28 women from the unilateral cohort with deleterious BRCA1/2 mutations had a lower prevalence of proliferative fibrocystic changes (PFC) (7%) compared with their matched control group (25%) (P = 0.075) and with patients who had a family history but no BRCA1/2 mutation (22–33%). None of the 11 deleterious mutation carriers from the bilateral cohort (0%) had PFC compared with 36% of women in the matched control group (P = 0.03). There was no major difference in the prevalence of other precursor lesions (including in situ carcinoma) in either cohort. Invasive carcinomas from the deleterious mutation carriers in the unilateral cohort were of higher grade compared with the control group (P = 0.003) and patients without a mutation (P < 0.0001) but were of similar grade compared with carriers of unclassified variant BRCA1/2 alterations (P = 0.20). Neoplastic lesions from the deleterious mutation carriers in the unilateral cohort had higher MIB‐1 proliferation indices compared with other patients with and without a family history of breast carcinoma. CONCLUSIONS: The current data suggest that the progression rate of breast neoplasia is accelerated in women who carry BRCA1/2 deleterious mutations compared with other patients who have breast carcinoma with or without a family history. This increased progression rate should be taken into account when considering the surveillance of asymptomatic women. Cancer 2003;97:1–11. © 2003 American Cancer Society. DOI 10.1002/cncr.11048

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.11048

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 36

  1. 10.4065/72.1.54 · DOI
  2. 10.1056/NEJM198705213162101 · DOI · Paper page
  3. 10.1677/erc.0.0080047 · DOI · Paper page
  4. 10.1007/s001090050128 · DOI · Paper page
  5. 10.1002/(SICI)1098-2388(200006)18:4<287::AID-SSU3>3.0.CO;2-5 · DOI · Paper page
  6. 10.1002/(SICI)1097-0142(19960215)77:4<697::AID-CNCR16>3.0.CO;2-W · DOI · Paper page
  7. 10.1002/(SICI)1097-0142(19990515)85:10<2200::AID-CNCR14>3.0.CO;2-S · DOI
  8. 10.1016/S0046-8177(98)90427-0 · DOI
  9. 10.1056/NEJM199901143400201 · DOI · Paper page
  10. 10.1200/JCO.2001.19.19.3938 · DOI · Paper page
  11. 10.1200/JCO.1998.16.7.2417 · DOI · Paper page
  12. Elston CW, 1998, The breast
  13. Page DL, 1987, Diagnostic histopathology of the breast
  14. 10.1002/(SICI)1097-0142(19971101)80:9<1798::AID-CNCR15>3.0.CO;2-0 · doi:10.1002/(sici)1097-0142(19971101)80:9<1798::aid-cncr15>3.0.co;2-0
  15. 10.1111/j.1365-2559.1991.tb00229.x · DOI · Paper page
  16. 10.1002/1097-0142(197710)40:4<1365::AID-CNCR2820400402>3.0.CO;2-N · DOI · Paper page
  17. 10.1126/science.2270486 · DOI
  18. 10.1093/jnci/50.5.1111 · doi:10.1093/jnci/50.5.1111
  19. 10.1093/jnci/90.9.697 · DOI · Paper page
  20. 10.1002/1097-0142(19930615)71:12<3896::AID-CNCR2820711217>3.0.CO;2-I · doi:10.1002/1097-0142(19930615)71:12<3896::aid-cncr2820711217>3.0.co;2-i
  21. Kamel OW, 1992, In situ proliferative epithelial lesions of the breast, Pathology., 1, 65
  22. 10.1001/jama.1992.03480070057030 · DOI · Paper page
  23. Fitzgibbons PL, 1998, Benign breast changes and the risk for subsequent breast cancer: an update of the 1985 consensus statement. Cancer Committee of the College of American Pathologists, Arch Pathol Lab Med., 122, 1053
  24. 10.1016/0046-8177(93)90243-A · doi:10.1016/0046-8177(93)90243-a
  25. 10.1093/oxfordjournals.aje.a112413 · DOI
  26. 10.1002/1097-0142(19871201)60:11<2751::AID-CNCR2820601127>3.0.CO;2-M · doi:10.1002/1097-0142(19871201)60:11<2751::aid-cncr2820601127>3.0.co;2-m
  27. 10.1093/jnci/90.15.1138 · DOI · Paper page
  28. 10.1101/gad.879201 · DOI · Paper page
  29. 10.1038/sj.onc.1204512 · DOI
  30. 10.1046/j.1365-2559.1997.5720795.x · doi:10.1046/j.1365-2559.1997.5720795.x
  31. 10.1186/bcr12 · DOI
  32. 10.1016/S1357-4310(98)01262-3 · DOI
  33. 10.1038/ng0495-444 · DOI · Paper page
  34. 10.1056/NEJM200102223440801 · DOI · Paper page
  35. 10.1001/jama.1921.02630320038011 · doi:10.1001/jama.1921.02630320038011
  36. 10.1002/cncr.10949 · DOI · Paper page

Cited by

See all 85

Metadata

Authors
Adem, C., Reynolds, C., Soderberg, C. L., Slezak, J. M., McDonnell, S. K., Sebo, T. J., Schaid, D. J., Myers, J. L., Sellers, T. A., Hartmann, L. C., & Jenkins, R. B.
Venue
Cancer
Publisher
Wiley
Published
2002-12-18
Volume
97
Issue
1
Pages
1-11
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W2023887123
Cited by
85
References
4
FWCI
3.17
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.